Paper Details

  1. Home
  2. Paper Details

Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.

Author: AgarwalArnav, BrahmbhattRonak, HamidJemila, JanoudiGhayath, LeeTaehoon, LillieErin, MacdonaldErin, PhamBa', RichterTrevor, ScottAlistair, SharpeJane P, StrausSharon E, ThomasSonia M, TriccoAndrea C, WarrenRachel

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Overview

This review evaluated the comparative effectiveness and safety of three intravitreal medications, bevacizumab, ranibizumab, and aflibercept, for treating various macular diseases including choroidal neovascular age-related macular degeneration (cn-AMD), diabetic macular edema (DMO), macular edema due to retinal vein occlusion (RVO-MO), and myopic choroidal neovascularisation (m-CNV). The review aimed to provide insights into the relative benefits and risks of these medications for different macular conditions.
Paper Details　
Original Abstract of the Article :
To evaluate the comparative effectiveness and safety of intravitreal bevacizumab, ranibizumab and aflibercept for patients with choroidal neovascular age-related macular degeneration (cn-AMD), diabetic macular oedema (DMO), macular oedema due to retinal vein occlusion (RVO-MO) and myopic choroidal n...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549720/

データ提供：米国国立医学図書館（NLM）

Anti-VEGF Treatment: A Beacon in the Desert of Retinal Diseases

Retinal diseases, such as age-related macular degeneration (AMD) and diabetic macular edema (DME), pose significant challenges to vision and overall health. This comprehensive systematic review and meta-analysis shed light on the effectiveness and safety of anti-vascular endothelial growth factor (VEGF) treatment for these conditions, providing a beacon in the vast desert of retinal research.

Comparing Anti-VEGF Agents: Choosing the Right Oasis

The authors compared the efficacy of three anti-VEGF agents: bevacizumab, ranibizumab, and aflibercept. The study evaluated their impact on patients with various retinal conditions, including AMD, DME, macular edema due to retinal vein occlusion, and myopic choroidal neovascularization. This is similar to exploring a desert and comparing different oases for their suitability based on factors like water availability, shade, and proximity to other resources.

Navigating the Desert of Retinal Research

While anti-VEGF agents have shown promise in treating retinal diseases, the researchers emphasize the need for further research to understand the long-term effects and optimal treatment strategies. This research is like carefully mapping a desert, with each study revealing more information about the landscape and its potential challenges.

Dr.Camel's Conclusion

This systematic review and meta-analysis provide valuable insights into the efficacy and safety of anti-VEGF agents in treating retinal conditions. While these agents hold promise, ongoing research is crucial to optimize their use and ensure the best possible outcomes for patients. Just as a desert traveler relies on maps and guidance, patients with retinal diseases benefit from ongoing research and the collaborative efforts of healthcare professionals.

Date :
  1. Date Completed 2020-04-16
  2. Date Revised 2020-04-16
Further Info :

Pubmed ID

31142516

DOI: Digital Object Identifier

PMC6549720

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.